BackNanobac Pharmaceuticals Overview

Nanobac Pharmaceuticals Long Term Debt

Track Nanobac Pharmaceuticals's long-term debt ($0) with charts, peers, and YoY trends.

Get informed when a big investor buys or sells

+ Follow
Long Term Debt
$0.00

Peer trimmed avg / median

Loading

Nanobac Pharmaceuticals Long Term Debt History

Loading

Nanobac Pharmaceuticals vs. peers: Long Term Debt Comparison

Loading

Nanobac Pharmaceuticals Long Term Debt Growth (YoY per quarter)

Latest change versus the prior comparable period (same company).

Loading

Balance Sheet Breakdown

Current CashShort Term InvestmentsReceivablesInventoryOther Current AssetsCurrent AssetsLong Term InvestmentsProperty Plant EquipmentGoodwillIntangible AssetsOther AssetsTotal AssetsNet Tangible AssetsAccounts PayableOther Current LiabilitiesTotal Current LiabilitiesLong Term DebtOther LiabilitiesMinority InterestTotal Liabilities

Nanobac Pharmaceuticals (NNBP) FAQ

The latest long-term debt for NNBP is $0 as of December 2007. In the prior-year period, the figure was $0. Investors often review this figure alongside Nanobac Pharmaceuticals's historical trend and sector peers before judging valuation or financial health.

Over the past year, NNBP's long-term debt moved from $0 to $0. If the trend continues in the same direction for several quarters, it can signal a meaningful shift in Nanobac Pharmaceuticals's operating scale or balance-sheet position.

A long-term debt figure of $0 for NNBP is a snapshot of scale on that line item. On its own it does not say whether the business is healthy — you also want growth rate, margins, and how the number compares with similar companies. Explore the charts below for those layers of context.

After noting NNBP's long-term debt ($0), review year-over-year change from $0, peer averages, and a few neighboring metrics such as revenue, margins, or valuation multiples. That combination usually beats staring at a single figure. The navigation links on this page jump you to those related views.

This page's peer comparison chart is the fastest way to stack Nanobac Pharmaceuticals's long-term debt against similar Healthcare names. You can also browse sector and industry screens on Stockcircle for a broader set of Healthcare companies and their key multiples and fundamentals.